Clinical Study

The Incidence of Various Antiphospholipid Antibodies, Measured by Commercial-Based Laboratory, with Recurrent Spontaneous Abortion and the Impact of Their Profiles on Reproductive Outcome with Active Anticoagulant Therapy

Nagayoshi Umehara and Tadao Tanaka

Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashii, Minato-ku, Tokyo 105-8461, Japan

Correspondence should be addressed to Tadao Tanaka, tanaka3520@jikei.ac.jp

Received 8 November 2011; Accepted 15 December 2011

Academic Editor: A. Martin-Hidalgo

Copyright © 2012 N. Umehara and T. Tanaka. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To investigate the incidence of various antiphospholipid antibodies (aPLs), measured by commercial-based laboratory, with recurrent spontaneous abortion (RSA) patients and the impact of species, isotype, titer, and number of positive aPLs on reproductive outcome in Japanese.

Method. In this retrospective cohort study, 263 patients with RSA without possible causes were investigated. Of 131 patients with one or more positive aPL, 82 pregnant women under anticoagulant therapy were evaluated.

Results. The incidence of various aPLs was almost consistent with previous report. Overall, successful pregnancy rate with anticoagulant therapy was 91.4% regardless of aPL profiles. There was no significant difference in the pregnancy maintenance rate between IgG and IgM groups or single positive and multiple positive groups, but there was a tendency for the rate with aspirin to be lower than with aspirin plus heparin in IgG group. Conclusion. aPL profile did not affect the pregnancy maintenance rate when anticoagulant therapy was actively introduced, however in IgG group, we recommend combination therapy with aspirin and heparin.

1. Introduction

Since the pathogenic association of antiphospholipid antibody (aPL) with recurrent spontaneous abortions (RSA) was reported, the efficacy of anticoagulant therapy for patients that have undergone RSA and have positive aPL has been investigated [1–4]. Regarding test items of aPLs for RSA, an international consensus statement concerning the update of the classification criteria for definite antiphospholipid syndrome (APS), published in February 2006 [5], specified only anticardiolipin antibody (aCL) of IgG and/or IgM isotype in a medium or high titer (over the 99th percentile), anticardiolipin-beta2 glycoprotein-I antibody (aβ2GPI) of IgG and/or IgM isotype (over the 99th percentile), and lupus anticoagulant (LA). For these patients met with above laboratory criteria and clinical criteria for APS, a treatment combining oral aspirin with the subcutaneous injection of unfractionated heparin has been regarded as superior to aspirin alone [6, 7]. However, various other aPLs, such as antiphosphatidylserine antibody (aPS) [8], antiphosphatidylethanolamine antibody (aPE) [9, 10], and others [11] have been considered to be involved in the etiology of RSA, but these aPLs are not mentioned in these revised classification criteria. Moreover, the relevance of isotypes, titer, or the number of positive aPLs in RSA has not been clarified. In fact, we see many RSA patients, not met the criteria for APS, but had one or more positive aPL. In the meantime, as for the detection of aPLs, laboratory criteria are not always reproducible because of well-known inter- and/or intralaboratory variability [12]. In Japan, a few facilities are testing aPLs in their own laboratory and in many other facilities, aPLs are measured by commercial-based laboratory reporting the 95th percentile and more as positive result, so the interpretation of the result needs to be careful.
On the other hand, almost all RSA patients with one or more positive aPL (the 95th percentile and more) prefer actively to be introduced an anticoagulant therapy for their next pregnancy.

Given the above background, we examined aPE and aPS of IgG and IgM antibodies in addition to LA, aβ2GPI, and aCL described in the classification criteria for definite APS and investigated the impact of antibody titers by classifying them into weakly (from the 95th to the 99th percentile) and strongly (over the 99th percentile), antibody isotypes of IgG and IgM, and the numbers of positive antibodies of single and multiple on reproductive outcome. We designed this retrospective cohort study, and our study focused on the incidence of various aPLs with RSA patients, measured by commercial-based laboratory and the impact of their profiles on reproductive outcomes with active anticoagulant therapy in order to develop individualization of treatment for patients with RSA, because the subcutaneous injection of heparin requires daily self-injection during the entire period of pregnancy, so this treatment is very stressful for patients.

2. Materials and Methods

2.1. Study Design. This retrospective cohort study was designed to evaluate the incidence of various aPLs, measured by commercial-based laboratory, in patients that had undergone RSA and to determine whether aPL profiles affect reproductive outcomes with the anticoagulant therapy in order to develop individualization of treatment in these patients. The Jikei University Institutional Review Board approved the study design.

2.2. Patients. Records were evaluated for 327 patients that had undergone RSA who visited the outpatient infertility clinic in Jikei University Hospital between November 2005 and July 2009. These patients had suffered 2 or more consecutive spontaneous abortions before the 12th week of gestation (= RSA patients) and were examined by routine checkup for RSA. Then, 64 patients were positive for routine checkup that included anatomical, endocrine, or chromosomal aberration, complications of SLE, or other autoimmune diseases. Of 263 patients negative for routine checkup, various aPLs were measured by commercial-based laboratory, defined 95th percentile and more as positive. Then 132 patients were negative for any aPLs and 131 patients revealed positive for one or more aPL.

These 131 patients were treated with the anticoagulant therapy, following which, 82 patients conceived. Of the 82 cases of conception, 74 maintained pregnancy successfully, and 8 cases had a miscarriage before the 12th week of pregnancy. Among these miscarriages, 7 cases exhibited normal karyotypes of aborted villi and 1 case had chromosomal aberration. Therefore, with the exception of the case involving chromosomal aberration, a total of 81 cases were analyzed for reproductive outcomes with the anticoagulant therapy. Pregnancy maintenance was defined as the pregnancy continuing beyond the 24th week and resulting in the delivery of a live-born neonate.

Figure 1 shows a summary of the patient groups and numbers investigated the incidences of aPLs and the reproductive outcomes with the anticoagulant therapy.
those higher than 3.5 U/mL as strongly positive. aCL-IgG was measured by ELISA using a MESACUP-IgG kit (MBL Co., Ltd., Japan), and values from 10 U/mL corresponding to the 95th percentile to 20 U/mL (almost the 99th percentile) were regarded as weakly positive and those higher than 20 U/mL as strongly positive. aCL-IgM was measured by ELISA using a kit from SRL Inc. (Japan), and values from 1.0 U/mL corresponding to the 95th percentile to 2.0 U/mL (almost the 99th percentile) were regarded as weakly positive and those higher than 2.0 U/mL as strongly positive. aPE-IgG, aPE-IgM, aPS-IgG, and aPS-IgM were measured as previously described [15, 16], and values from 0.300, 0.450, 1.0, and 1.66 IU/mL, corresponding to the 95th percentile and more, were regarded as strongly positive [16, 17] and those higher than 20 U/mL corresponding to almost the 99th percentile, the positive rates of aPL ranged from 0% (1/263: aβ2GPI) to 19.4% (51/263: aPS-IgM), and in the strongly positive group (over the 99th percentile), those of aPL ranged from 0% (0/263: aβ2GPI) to 8.4% (22/263: aPS-IgM). Comparing the incidence between these two groups, a higher incidence was found in the weakly positive group in all species of aPLs naturally.

3.2. Reproductive Outcomes of the Active Anticoagulant Therapy in RSA Patients with aPL. The impact of various aPL profiles on reproductive outcomes was shown in Tables 2 and 3. Of the 131 patients treated with the active anticoagulant therapy by the method mentioned above, 82 cases led to conception. After the exclusion of one case with chromosomal aberration of aborted villi, 81 cases were finally analyzed for reproductive outcomes. Total successful pregnancy rate was 91.4% (74/81). For these 81 patients, the mean age was 33.8 ± 4.0 years, and the mean number of spontaneous abortions was 2.8 ± 0.9. When the 81 patients were divided into 74 cases of successfully maintained pregnancy and 7 cases of abortion, the mean ages were 33.8 ± 4.1 and 34.4 ± 4.0 years, and the mean numbers of spontaneous abortions were 2.8 ± 1.0 and 2.7 ± 0.8, respectively. No significant differences were found between these groups. Concerning the variety of aPLs without titer, the rate of pregnancy maintenance of 88.1% (37/42) in aPS-IgM positive cases was the lowest among the various aPLs. However, no significant difference was found between all of each eight aPLs. For instance, the P value of the difference between aCL-IgG (the highest rate of pregnancy maintenance: 100%) and aPS-IgM (the lowest rate of pregnancy maintenance: 88.1%) was 0.176, and that of aCL-IgG versus aPS-IgG was 0.277. As for the impact of the titer of aPLs, comparing the rate of pregnancy maintenance in the weakly positive group with that in the strongly positive group for each aPL, no significant difference was found among the six aPLs (IgG and IgM of aCL, aPE, and aPS), and LA or aβ2GPI strongly positive case was not here. For instance, the lowest P value between weakly and strongly positive groups was 0.312 for aPE-IgG. As for the type (IgG or IgM group) and the number (single positive or multiple positive group) of positive aPLs, the impact of these on reproductive outcomes was investigated. (Table 3) Eighty-one cases were divided into two groups. The IgM group contained 40 cases with only IgM-positive results and the IgG group contained 41 cases with at least one IgG-positive result. The rate of pregnancy maintenance in the IgM group was 90% (36/40), and that in the IgG group was 92.7% (37/41), showing no significant difference between these two groups (P value: 0.667). As for the number of positive aPLs, the rate of pregnancy maintenance in the 34 cases with a single positive group, with only one positive aPL, was 91.2% (31/34) and that in 47 cases with multiple positive group, with two or more positive aPLs, was 91.5% (43/47), also showing no significant difference between these two groups (P value: 0.961).
Table 1: Incidence of various aPL profiles in RSA patients without possible causes.

| aPL type and titer | aPL type | Positive/tested (positive rate; %) | aPL titer | Positive/tested (positive rate; %) |
|--------------------|----------|-----------------------------------|-----------|-----------------------------------|
| LA                 |          | 47/263 (17.9%)                    | 45/263 (17.1%) |
| weakly             |          | 45/263 (17.1%)                    | 2/263 (0.8%)  |
| strongly           |          | 0/263 (0%)                        |            |
| aβ2GPI             |          | 1/263 (0.4%)                      | 1/263 (0.4%) |
| weakly             |          | 0/263 (0%)                        | 0/263 (0%)  |
| strongly           |          | 0/263 (0%)                        | 0/263 (0%)  |
| aCL-IgG            |          | 23/263 (8.7%)                     | 12/263 (4.6%) |
| weakly             |          | 12/263 (4.6%)                     | 11/263 (4.2%) |
| strongly           |          | 11/263 (4.2%)                     |            |
| -IgM               |          | 71/263 (27.0%)                    | 50/263 (19.0%) |
| weakly             |          | 50/263 (19.0%)                    | 21/263 (8.0%) |
| strongly           |          | 21/263 (8.0%)                     |            |
| aPE-IgG            |          | 31/263 (11.8%)                    | 22/263 (8.4%) |
| weakly             |          | 22/263 (8.4%)                     | 9/263 (3.4%)  |
| strongly           |          | 9/263 (3.4%)                      |            |
| -IgM               |          | 31/263 (11.8%)                    | 23/263 (8.7%) |
| weakly             |          | 23/263 (8.7%)                     | 8/263 (3.0%)  |
| strongly           |          | 8/263 (3.0%)                      |            |
| aPS-IgG            |          | 17/263 (6.5%)                     | 12/263 (4.6%) |
| weakly             |          | 12/263 (4.6%)                     | 5/263 (1.9%)  |
| strongly           |          | 5/263 (1.9%)                      |            |
| -IgM               |          | 73/263 (27.8%)                    | 51/263 (19.4%) |
| weakly             |          | 51/263 (19.4%)                    | 22/263 (8.4%) |
| strongly           |          | 22/263 (8.4%)                     |            |

Positive titers of aPLs were defined as follows:
LA: weakly; from 1.12 to 1.30, strongly; over 1.30.
aβ2GPI: weakly; from 1.9 to 3.5 U/mL, strongly; over 3.5 U/mL.
aCL-IgG: weakly; from 10 to 20 U/mL, strongly; over 20 U/mL.
aCL-IgM: weakly; from 1.0 to 2.0 U/mL, strongly; over 2.0 U/mL.
aPE-IgG: weakly; from 0.3 to 0.5 U/mL, strongly; over 0.5 U/mL.
aPE-IgM: weakly; from 0.45 to 0.75 U/mL, strongly; over 0.75 U/mL.
aPS-IgG: weakly; from 1.0 to 1.66 U/mL, strongly; over 1.66 U/mL.
aPS-IgM: weakly; from 1.0 to 1.66 U/mL, strongly; over 1.66 U/mL.

3.3. The Therapeutic Outcome of the Two Regimens by the Isotype and Number of Positive aPLs. Finally, we intended to identify a therapeutic principle for RSA patients with aPL. Table 4 showed how the two regimens of anticoagulant therapy, aspirin alone and aspirin plus heparin, impacted on the reproductive outcomes, showing the results for the isotype of positive aPLs or the number of positive aPLs. There was a tendency for the rate of pregnancy maintenance with aspirin alone to be lower than that with aspirin plus heparin in the IgG group however, this did not constitute a significant difference (P value: 0.077). In IgM, single positive and multiple positive group, there was no difference in pregnancy maintenance rate between these two regimens.

4. Discussion
In the field of obstetrics, APS has been mainly investigated with regard to its relationship with pregnancy loss, and therapy for aPL-positive recurrent pregnancy loss has been studied. Although many points concerning the mechanism of aPL-induced pregnancy loss remain unclear, according to a systemic review of RCT by Empson et al. [6], the following results have been shown. (1) A treatment combining low-dose oral aspirin plus twice-a-day subcutaneous injections of unfractionated heparin is beneficial for patients with aPL-positive recurrent pregnancy loss without other causes of infertility, although its efficacy for low-risk patient is not clear. (2) Low-molecular-weight heparin is effective, although whether it exhibits an effect equivalent to that of unfractionated heparin is not clear; the clarification of this issue will require a large-scale RCT. (3) There is no evidence for the efficacy of other therapies such as immunoglobulin and steroid treatments. As a consequence, anticoagulant therapy mainly consisting of a combination of aspirin and unfractionated heparin has become a standard therapy for patients with aPL-positive recurrent pregnancy loss, and currently many facilities perform this treatment as a standard therapy. However, it should be kept in mind that the clinical backgrounds of patients, the aPL species investigated, and
Table 2: Reproductive outcomes of the anticoagulant therapy according to various aPL profiles in RSA patients.

| aPL species and titer | Establisheda (n) | Maintaineda (n) | Aborteda (n) | Success rate (%) | P value (weakly versus strongly) |
|-----------------------|-----------------|----------------|-------------|-----------------|---------------------------------|
|                       | total 81        | total 74       | total 7     |                 |                                 |
| LA                    |                 |                |             |                 |                                 |
| weakly                | 32              | 30             | 2           | 93.8            | 93.8                            |
| strongly              | 0               | 0              | 0           | —               | —                               |
| aβ2GPI                |                 |                |             |                 |                                 |
| weakly                | 1               | 1              | 0           | 100             | 100                             |
| strongly              | 0               | 0              | 0           | —               | —                               |
| aCL-IgG               |                 |                |             |                 |                                 |
| weakly                | 6               | 6              | 0           | 100*,**         | 100                             |
| strongly              | 8               | 8              | 0           | 100             | 100                             |
| -IgM                  |                 |                |             |                 |                                 |
| weakly                | 25              | 24             | 1           | 95.0            | 96.0                            |
| strongly              | 15              | 14             | 1           | 93.3            | 0.708                           |
| aPE-IgG               |                 |                |             |                 |                                 |
| weakly                | 17              | 15             | 2           | 92.0            | 88.2                            |
| strongly              | 8               | 8              | 0           | 100             | 0.312                           |
| -IgM                  |                 |                |             |                 |                                 |
| weakly                | 12              | 11             | 1           | 94.1            | 91.7                            |
| strongly              | 5               | 5              | 0           | 100             | 0.506                           |
| aPS-IgG               |                 |                |             |                 |                                 |
| weakly                | 6               | 5              | 1           | 90.0**          | 83.3                            |
| strongly              | 4               | 4              | 0           | 100             | 0.389                           |
| -IgM                  |                 |                |             |                 |                                 |
| weakly                | 28              | 24             | 4           | 88.1*           | 85.7                            |
| strongly              | 14              | 13             | 1           | 82.9            | 0.500                           |

*Some patients had multiple positive aPLs.
P value for * was 0.176 and for ** was 0.227.

Table 3: Reproductive outcomes of the anticoagulant therapy according to isotypes and the number of positive aPL in RSA patients.

| The isotype or number of positive aPL | Conceived | Maintained | Aborted | Successful pregnancy rate (%) | P value |
|--------------------------------------|-----------|------------|---------|-------------------------------|---------|
| IgG groupa                           | 41        | 38         | 3       | 92.7                          | a versus b = 0.667 |
| IgM groupb                           | 40        | 36         | 4       | 90.0                          |         |
| Single positive groupc               | 34        | 31         | 3       | 91.2                          | c versus d = 0.961 |
| Multiple positive groupd             | 47        | 43         | 4       | 91.5                          |         |

*aIgG group.
bIgM Group.
cSingle positive group.
dMultiple positive group.

The criteria of antibody titers are not necessarily consistent among these reports. The laboratory criteria described in the classification criteria for APS are limited to aCL of IgG or IgM isotype in a medium or higher titer, aβ2GPI of IgG or IgM isotype, and LA. Sugi et al. reported a higher frequency of aPE in patients with recurrent pregnancy loss before the 10th week of gestation than in healthy women: the frequencies of aPE-IgG, aPE-IgM, and aPE-IgA were 20.1%, 12.2%, and 1.4% in the patients, respectively, which were significantly higher than those in healthy women. These findings suggested that aPE is strongly associated with early pregnancy loss [9] and that aPE testing in addition to aPL examinations of patients with infertility is advisable. Rote et al. detected aPS at higher frequencies (IgG: 87%, IgM: 40%) than aCL (IgG: 68%, IgM: 36%) in patients with idiopathic recurrent pregnancy loss, suggesting a strong association of aPS with early pregnancy loss [8] and indicating the importance of aPS testing. Pregnancy loss was considered to occur at a high frequency in pregnant women with LA and high titers of aCL-IgG [18, 19], and the risks of pregnancy loss and obstetric complications in pregnant women with low titers of aCL-IgG and aCL-IgM were found to be similar.
to those in pregnant women negative for these antibodies [20], while low titers of aPL were not found to be clinically significant [21]. The clinical significance of the aPL isotypes other than IgG, such as IgM and IgA, including aCL, is still unclear. Matzner et al. investigated 6 species of aPL including aCL in 352 patients with recurrent pregnancy loss and detected aPL in about 60% of the patients, but the antibodies were IgM in 75% of patients [22], suggesting that the IgM antibodies were also pathogenic. However, the rate of pregnancy loss due to aCL-IgM alone was found to be similar to that in aPL-negative women [20]. Moreover, Aoki et al. reported that fetal loss occurred in 27 cases (82%) out of 33 IgG aPL-positive patients when testing aPE, aPS, antiphosphatidylinsitol antibody (aPI), and aCL without treatment and in 2 cases (40%) out of 5 IgG aPL-negative but IgM aPL-positive patients, and fetal loss occurred in all 21 patients that were aPL-positive with two or more IgG types. They concluded that the IgG isotype of aPLs was more pathogenic than that of IgM and two or more IgG-positive cases were more at risk than one-IgG-positive cases [23].

In this study, concerning individual aPL without regarding the titer, the positive rates of aCL-IgM and aPS-IgM exceeded 25%, while that of aβ2GPI was very low, only 0.4%. Those of other aPLs were found to be between 6.5% (aPS-IgG) and 17.9% (LA). This high positive rate, regarded the 95th percentile and more as positive, for aCL-IgM and aPS-IgM in RSA women was five times as high as normal Japanese population, and aCL and aPS may have had stronger association with RSA than aβ2GPI, consistent with previous reports [8, 22]. With regard to the isotype of aPL, the positive rates of aCL-IgM and aPS-IgM were very high, and those of CL-IgG (8.7%) and aPS-IgG (6.5%) were lower than aCL-IgM and aPS-IgM, suggesting that the IgM isotype of aPLs may also have been pathogenic for early RSA, and these antibodies are worth testing in RSA women. Moreover, strongly positive case (over the 99th percentile) of LA and aβ2GPI were more scarcer than normal Japanese population (0.8% and 0%, resp.), suggesting relatively high association with early RSA and IgG or IgM of aCL, aPE, and aPS.

With regard to the reproductive outcome of the anticoagulant therapy in patients that had undergone RSA and had any aPLs, the rate of pregnancy maintenance of 88.1% (37/42) in aPS-IgM-positive cases was the lowest, but there was no significant difference among the other eight aPLs in terms of the rate of pregnancy maintenance. There was no LA and aβ2GPI for strongly positive conceived patient in this study, with regard to the titer of each aPL, upon comparing the pregnancy maintenance rate of weakly positive with strongly positive groups for each aPL, no significant differences were found for all 8 aPLs (Table 2). As mentioned before [18, 19], pregnant women with LA and/or high titer of aCL-IgG were thought to be high risk of RSA, but in fact, the rate of pregnancy maintenance of LA weakly positive RSA patients is 93.8% and that of aCL-IgG strongly positive RSA patients is 100%. No significant difference due to aPL species or titer in the pregnancy maintenance rate was identified in this study. Active anticoagulant therapy enabled the normal maintenance of pregnancy regardless of the positive antibody species and titer, and normal pregnancy was maintained in 91.4% of cases on average.

Next, we investigated the impacts of the isotype of aPLs, namely, IgG group or IgM group, and the number of positive aPLs, namely, single or multiple, on reproductive outcomes. All patients with positive LA or aβ2GPI had other aPLs measured in this study. The rate of pregnancy maintenance in the IgM group was 90.0% and that in the IgG group was 92.7%, showing no significant difference. With regard to the number of positive aPLs, the rate of pregnancy maintenance in 34 cases with single aPL was 91.2% and that in 47 cases with multiple aPLs was 91.5%, also showing no significant difference (Table 3), so we concluded that active anticoagulant therapy for aPL positive RSA patients will result in good pregnancy outcome regardless of the isotype and the number of positive aPLs.

Table 4: Reproductive outcomes in patients with RSA with aPL according to the kind of anticoagulant therapy.

| kind of therapy     | The isotype or number of positive aPL | Pregnancy (n) | Successful pregnancy rate (%) | P value |
|---------------------|--------------------------------------|---------------|------------------------------|---------|
|                     | Established | Maintained | Aborted                      |         |
| Aspirin alone       |            |            |                              |         |
| IgG group           | 15         | 13         | 2                            | 86.7    | b versus |
| IgM group           | 13         | 12         | 1                            | 90.9    | f = 0.519 |
| Multiple positive   | 11         | 10         | 1                            | 90.9    | f = 0.519 |
| Aspirin + heparin   |            |            |                              |         |
| IgG group           | 31         | 30         | 1                            | 96.8    | c versus |
| IgM group           | 24         | 21         | 3                            | 87.5    | g = 0.410 |
| Multiple positive   | 19         | 18         | 1                            | 94.7    | d versus |
|                     | 36         | 33         | 3                            | 91.7    | h = 0.937 |

*a* IgG group with aspirin.  
*b* IgM Group with aspirin.  
*c* Single positive group with aspirin.  
*d* Multiple positive group with aspirin.  
*e* IgG group with aspirin plus heparin.  
*f* IgM Group with aspirin plus heparin.  
*g* Single positive group with aspirin plus heparin.  
*h* Multiple positive group with combination therapy of aspirin plus heparin.
Finally, we intended to identify a therapeutic principle for RSA patients with aPL. There was a tendency for the rate of pregnancy maintenance with aspirin alone to be lower than that with aspirin plus heparin in the IgG group; however, no significant difference was found (P value: 0.077), showing a benefit of combination therapy for IgG group and higher pathogenicity in the IgG than IgM group. Moreover, the rate of pregnancy maintenance did not differ between patients treated with aspirin alone and those with a combination of aspirin plus heparin in the IgM group, so aspirin therapy alone is sufficient for the IgM group because heparin therapy was very stressful for patients. As mentioned before [20, 22, 23], the clinical significance of the aPLs isotype of IgM was not clear, but IgM isotype may have had some pathogenicity for early recurrent abortion and may have been weaker than that of IgG.

A limitation of this study may be the consideration of the pregnancy maintenance rate without control patients (without anticoagulant therapy), including patient overlap for aPL positivities and not RCT but retrospective cohort study. This pregnancy maintenance rate is as high as normal Japanese population after an intrauterine pregnancy has been seen by ultrasound, and this study may include normal population because we have resulted from the 95th to the 99th percentile as weakly positive. The interpretation of the population because we have resulted from the 95th to the 99th percentile as weakly positive. The interpretation of the results needs to be careful and the accumulation of additional cases and more detailed investigations may be necessary.

5. Conclusion

Because IgG or IgM of aCL, aPE, and aPS were more frequent than LAC or aβ2GPI in RSA patients, we have to test these aPLs for RSA patients checkup. The patients suffering from RSA with some aPLs and do not meet criteria for APS resulted in normal pregnancy outcome by active anticoagulant therapy regardless of the positive antibody species, titer, and the number. In terms of the pathogenicity of aPLs, IgG isotype may be stronger than IgM isotype, so we recommend combination therapy with aspirin and heparin for IgG-positive RSA patients.

Conflict of Interests

All authors have no conflict of interests to declare.

References

[1] M. Lockshin, M. Druzin, S. Goei et al., “Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus,” The New England Journal of Medicine, vol. 313, no. 3, pp. 152–156, 1985.
[2] D. Branch, J. Scott, N. Kochenour, and E. Hershgold, “Obstetric complications associated with the lupus anticoagulant,” New England Journal of Medicine, vol. 313, no. 21, pp. 1322–1326, 1985.
[3] E. Harris, J. Chan, R. Asherton, V. Aber, A. Gharavi, and G. Hughes, “Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin antibody test,” Archives of Internal Medicine, vol. 146, no. 11, pp. 2153–2156, 1986.
[4] G. Hughes, N. Harris, and A. Gharavi, “The anticardiolipin syndrome,” The Journal of Rheumatology, vol. 13, no. 3, pp. 486–489, 1986.
[5] S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of classification criteria for definite anti-phospholipid syndrome (APS),” Journal of Thrombosis, vol. 4, no. 2, pp. 295–306, 2006.
[6] M. Empson, M. Lassere, J. Craig, and J. Scott, “Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD002859, 2005.
[7] R. Rai, H. Cohen, M. Dave, and L. Regan, “Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies),” British Medical Journal, vol. 314, no. 7076, pp. 253–257, 1997.
[8] N. S. Rote, D. Dostal-Johnson, and D. W. Branch, “Antiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin,” American Journal of Obstetrics and Gynecology, vol. 163, no. 2, pp. 575–584, 1990.
[9] T. Sugi, J. Katsunuma, S. Izumi, J. A. McIntyre, and T. Makino, “Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses,” Fertility and Sterility, vol. 71, no. 6, pp. 1060–1065, 1999.
[10] T. Sugi, H. Matsubayasi, A. Inomo, L. Dan, and T. Makino, “Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss,” The Journal of Obstetrics and Gynecology Research, vol. 30, no. 4, pp. 326–332, 2004.
[11] D. L. Yetman and W. H. Kutteh, “Antiphospholipid antibody panels and recurrent pregnancy loss. Prevalence of antiphospholipid antibodies compared with other antiphospholipid antibodies,” Fertility and Sterility, vol. 66, no. 4, pp. 540–546, 1996.
[12] A. Tincani, M. Filippini, and M. Scarsi, “European attempts for the standardisation of the antiphospholipid antibodies,” Lupus, vol. 18, no. 10, pp. 913–919, 2009.
[13] P. Thiagarajan, V. Pendo, and S. S. Shapiro, “The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants,” Blood, vol. 68, no. 4, pp. 869–874, 1986.
[14] N. Ozawa, T. Makino, H. Matsubayashi et al., “β2-GPI-dependent and independent binding of antiphospholipid antibodies in patients with recurrent spontaneous abortions,” Journal of Clinical Laboratory Analysis, vol. 8, no. 5, pp. 255–259, 1994.
[15] E. Matsuura, Y. Igarashi, M. Fujimoto et al., “Heterogeneity of antiphospholipid antibodies defined by the antiphospholipid cofactor,” Journal of Immunology, vol. 148, no. 12, pp. 3885–3891, 1992.
[16] T. Sugi and J. A. McIntyre, “Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex,” Blood, vol. 86, no. 8, pp. 3083–3089, 1995.
[17] J. A. McIntyre, D. R. Wagenknecht, and W. P. Faulk, “Antiphospholipid antibodies in heart transplant recipients,” Clinical Cardiology, vol. 18, no. 10, pp. 575–580, 1995.
[18] M. D. Lockshin, T. Qamar, M. L. Druzin, and S. Goei, “Antibody to cardiolipin, lupus anticoagulant, and fetal death,” Journal of Rheumatology, vol. 14, no. 2, pp. 259–262, 1987.
[19] R. S. Rai, K. Clifford, H. Cohen, and L. Regan, “High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies,” Human Reproduction, vol. 10, no. 12, pp. 3301–3304, 1995.

[20] R. M. Silver, T. F. Porter, I. van Leeuween, G. Jeng, J. R. Scott, and D. W. Branch, “Anticardiolipin antibodies: clinical consequences of ‘low titers’,” Obstetrics and Gynecology, vol. 87, no. 4, pp. 494–500, 1996.

[21] S. Wu and M. D. Stephenson, “Obstetrical antiphospholipid syndrome,” Seminars in Reproductive Medicine, vol. 24, no. 1, pp. 40–53, 2006.

[22] W. Matzner, P. Chong, G. Xu, and W. Ching, “Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 39, no. 1, pp. 27–30, 1994.

[23] K. Aoki, Y. Hayashi, Y. Hirao, and Y. Yagami, “Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss,” American Journal of Reproductive Immunology, vol. 29, no. 2, pp. 82–87, 1993.